Cargando…

Harnessing tumor-associated macrophages as aids for cancer immunotherapy

Cancer immunotherapies that engage immune cells to fight against tumors are proving to be powerful weapons in combating cancer and are becoming increasingly utilized in the clinics. However, for the majority of patients with solid tumors, little or no progress has been seen, presumably due to lack o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaolei, Liu, Rui, Su, Xiao, Pan, Yongsha, Han, Xiaofeng, Shao, Changshun, Shi, Yufang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894344/
https://www.ncbi.nlm.nih.gov/pubmed/31805946
http://dx.doi.org/10.1186/s12943-019-1102-3
_version_ 1783476374725459968
author Li, Xiaolei
Liu, Rui
Su, Xiao
Pan, Yongsha
Han, Xiaofeng
Shao, Changshun
Shi, Yufang
author_facet Li, Xiaolei
Liu, Rui
Su, Xiao
Pan, Yongsha
Han, Xiaofeng
Shao, Changshun
Shi, Yufang
author_sort Li, Xiaolei
collection PubMed
description Cancer immunotherapies that engage immune cells to fight against tumors are proving to be powerful weapons in combating cancer and are becoming increasingly utilized in the clinics. However, for the majority of patients with solid tumors, little or no progress has been seen, presumably due to lack of adequate approaches that can reprogram the local immunosuppressive tumor milieu and thus reinvigorate antitumor immunity. Tumor-associated macrophages (TAMs), which abundantly infiltrate most solid tumors, could contribute to tumor progression by stimulating proliferation, angiogenesis, metastasis, and by providing a barrier against antitumor immunity. Initial TAMs-targeting strategies have shown efficacy across therapeutic modalities and tumor types in both preclinical and clinical studies. TAMs-targeted therapeutic approaches can be roughly divided into those that deplete TAMs and those that modulate TAMs activities. We here reviewed the mechanisms by which macrophages become immunosuppressive and compromise antitumor immunity. TAMs-focused therapeutic strategies are also summarized.
format Online
Article
Text
id pubmed-6894344
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68943442019-12-11 Harnessing tumor-associated macrophages as aids for cancer immunotherapy Li, Xiaolei Liu, Rui Su, Xiao Pan, Yongsha Han, Xiaofeng Shao, Changshun Shi, Yufang Mol Cancer Review Cancer immunotherapies that engage immune cells to fight against tumors are proving to be powerful weapons in combating cancer and are becoming increasingly utilized in the clinics. However, for the majority of patients with solid tumors, little or no progress has been seen, presumably due to lack of adequate approaches that can reprogram the local immunosuppressive tumor milieu and thus reinvigorate antitumor immunity. Tumor-associated macrophages (TAMs), which abundantly infiltrate most solid tumors, could contribute to tumor progression by stimulating proliferation, angiogenesis, metastasis, and by providing a barrier against antitumor immunity. Initial TAMs-targeting strategies have shown efficacy across therapeutic modalities and tumor types in both preclinical and clinical studies. TAMs-targeted therapeutic approaches can be roughly divided into those that deplete TAMs and those that modulate TAMs activities. We here reviewed the mechanisms by which macrophages become immunosuppressive and compromise antitumor immunity. TAMs-focused therapeutic strategies are also summarized. BioMed Central 2019-12-05 /pmc/articles/PMC6894344/ /pubmed/31805946 http://dx.doi.org/10.1186/s12943-019-1102-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Li, Xiaolei
Liu, Rui
Su, Xiao
Pan, Yongsha
Han, Xiaofeng
Shao, Changshun
Shi, Yufang
Harnessing tumor-associated macrophages as aids for cancer immunotherapy
title Harnessing tumor-associated macrophages as aids for cancer immunotherapy
title_full Harnessing tumor-associated macrophages as aids for cancer immunotherapy
title_fullStr Harnessing tumor-associated macrophages as aids for cancer immunotherapy
title_full_unstemmed Harnessing tumor-associated macrophages as aids for cancer immunotherapy
title_short Harnessing tumor-associated macrophages as aids for cancer immunotherapy
title_sort harnessing tumor-associated macrophages as aids for cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894344/
https://www.ncbi.nlm.nih.gov/pubmed/31805946
http://dx.doi.org/10.1186/s12943-019-1102-3
work_keys_str_mv AT lixiaolei harnessingtumorassociatedmacrophagesasaidsforcancerimmunotherapy
AT liurui harnessingtumorassociatedmacrophagesasaidsforcancerimmunotherapy
AT suxiao harnessingtumorassociatedmacrophagesasaidsforcancerimmunotherapy
AT panyongsha harnessingtumorassociatedmacrophagesasaidsforcancerimmunotherapy
AT hanxiaofeng harnessingtumorassociatedmacrophagesasaidsforcancerimmunotherapy
AT shaochangshun harnessingtumorassociatedmacrophagesasaidsforcancerimmunotherapy
AT shiyufang harnessingtumorassociatedmacrophagesasaidsforcancerimmunotherapy